Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.66 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | CASP1 | P29466 | 1/20 | 0.66 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3646685 | 0.86 | TSHR (0.66) | TSHRNPSR1HSD17B10ALOX15CASP1 | |
| SCHEMBL7096171 | 0.82 | RAB9A (0.66) | TSHRNPSR1HSD17B10SIRT2KMT2A | |
| SCHEMBL18398726 | 0.82 | KMT2A (0.74) | TSHRNPSR1HSD17B10ALOX15CASP1 | |
| SCHEMBL45148 | 0.82 | KMT2A (0.73) | TSHRNPSR1HSD17B10ALOX15CASP1 | |
| SCHEMBL6642201 | 0.80 | KMT2A (0.67) | TSHRNPSR1HSD17B10ALOX15CASP1 | |
| SCHEMBL29238994 | 0.80 | KMT2A (0.71) | TSHRNPSR1HSD17B10ALOX15CASP1 | |
| SCHEMBL30533391 | 0.80 | KMT2A (0.71) | TSHRNPSR1HSD17B10ALOX15CASP1 | |
| SCHEMBL16964864 | 0.80 | NAMPT (0.50) | NPSR1HSD17B10KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL1520310 | 0.79 | NPC1 (0.65) | HSD17B10KMT2ASMN1; SMN2RAB9ANPC1 | |
| SCHEMBL24006426 | 0.79 | ACVRL1 (0.53) | MAPTKDM4CPTGS1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246915-A1 | AMINONAPHTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2024-07-25 | — | — | US | disclosed |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2024-03-05 | — | — | US | disclosed |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2024-03-05 | — | — | US | disclosed |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2024-03-05 | — | — | US | disclosed |
| EP-3324954-B1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | CALGENT BIOTECHNOLOGY CO LTD (TW) | 2022-03-09 | — | — | EP | disclosed |
| EP-3324954-B1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | CALGENT BIOTECHNOLOGY CO LTD (TW) | 2022-03-09 | — | — | EP | disclosed |
| US-20200148643-A1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2020-05-14 | — | — | US | disclosed |
| US-20200148643-A1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2020-05-14 | — | — | US | disclosed |
| US-10577328-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | TAIPEI MEDICAL UNIVERSITY (TW) | 2020-03-03 | — | — | US | disclosed |
| US-10577328-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | TAIPEI MEDICAL UNIVERSITY (TW) | 2020-03-03 | — | — | US | disclosed |
| US-20180319749-A1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | CALGENT BIOTECHNOLOGY CO., LTD. (TW) | 2018-11-08 | — | — | US | disclosed |
| EP-3324954-A1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | Taipei Medical University (TW) | 2018-05-30 | — | — | EP | disclosed |
| WO-2017014788-A1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | TAIPEI MEDICAL UNIVERSITY (CN) | 2017-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148643-A1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | UBQLN1, UBQLN2, PSMB1 | TSHR 4325/4885NPSR1 3481/4885HSD17B10 2097/4885 |
| US-10577328-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | PSMB1, UBQLN1, PSMB5 | TSHR 4639/4885NPSR1 3443/4885HSD17B10 2360/4885 |
| US-20180319749-A1 | AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | UBQLN1, UBQLN2, PSMB1 | TSHR 4325/4885NPSR1 3481/4885HSD17B10 2097/4885 |
| US-11919858-B2 | Aminonapthoquinone compounds and pharmaceutical composition for blocking ubiquitination-proteasome system in diseases | UBQLN1, PSMB1, UBQLN2 | TSHR 4572/4885NPSR1 3271/4885HSD17B10 1828/4885 |
| US-20240246915-A1 | AMINONAPHTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES | UBQLN1, ADRM1, UBQLN2 | TSHR 4698/4885NPSR1 3962/4885HSD17B10 1410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.